Research
Hormonal
Western dietary patterns (high fat/sugar) cause gut dysbiosis and 'leaky gut' (increased permeability), allowing bacterial endotoxins (LPS) to enter circulation, triggering systemic and neuro-inflammation.
Eating a Western diet (high fat/sugar, low fiber) damages your gut barrier, letting toxins into your blood and brain, causing inflammation. To protect your brain, prioritize fiber and reduce saturated fats to support a healthy gut barrier and reduce inflammation.
ModerateSupportsMEDIUM confidence
Westernized dietary patterns are known to be a major cause of the obesity epidemic, which also promotes a dysbiotic drift in the gut microbiota; this, in turn, seems to contribute to obesity-related complications... Dietary saturated fatty acids (SFAs) can induce inflammatory responses... SFAs are able to activate the TLRs... leading to cerebral inflammation... The dysbiotic microbiota associated with obesity can also contribute to increasing the inflammatory tone via activation of TLRs...
Why this rating
Review paper citing multiple animal studies and some human observational links; mechanism is well-supported in animals, less so in humans.
Source
Interplay Between the Gut-Brain Axis, Obesity and Cognitive Function
Ana Agustí et al. · Frontiers in Neuroscience · 2018
DOI 10.3389/fnins.2018.00155
narrative_reviewCited 295×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-associated gut dysbiosis contributes to cognitive and mood deficits through the activation of the HPA-axis, leading to glucocorticoid overproduction, and the promotion of a pro-inflammatory milieu (endotoxemia/leaky gut) that causes neuro-inflammation.Moderate
- Specific probiotic strains (e.g., Bifidobacterium pseudocatenulatum CECT 7765) can reduce stress-induced corticosterone levels and improve depressive-like behavior in obese animal models by modulating the gut microbiota.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →